



VirusSure is a privately owned company specialising in the virus and prion safety testing of biopharmaceutical products and offers a breadth of experience as well as unparalleled customer service. Both our *in vitro* and *in vivo* testing facilities are certified to GLP/GMP standards operated under a state of the art risk based quality management system .

Our goal is simple- to be a world leader in contract virus and prion safety testing. We have a strong commitment to customer service and quality, and have built a strong scientific team to keep us at the forefront of technology.

An Experienced Management Team

Developing an effective pathogen safety testing program has always involved the investment of significant time and resources. It is a challenge that without experience is difficult to achieve. We have maximised the available experience through the careful selection of management and Supervisory Board members.


A Commitment to Quality and Customer Service

At VirusSure, customers come first, and we strive to ensure that we deliver a high quality service. From initial contact through development of a strategy and study performance and reporting, a strong emphasis on quality is present throughout. A quality service requires well educated staff, and therefore VirusSure focuses a strong emphasis on staff training and communication of our strategies.

Technological Innovation

Developing the right strategy may require the development of new tests, or the application of existing tests in modified formats. Technologically, VirusSure is at the forefront of virus and prion safety testing

To take advantage of our friendly and professional service, please contact us through our website at www.virusure.com, or via email: Andy_Bailey@virusure.com





VirusSure specialises in performance of the following biosafety testing services.

Virus Clearance Studies

Virus clearance studies remain one of the key pillars of the safety tripod for ensuring product safety, and for many products may represent the main avenue for ensuring the safety of the product. The design, implementation and performance of virus clearance studies therefore remains an area of intense focus during regulatory review of submissions.

Prion Clearance Studies

VirusSure also has extensive experience in the performance of prion clearance studies, which can be performed either using a Western blot assay or by *in vivo* bio-assay at our GLP/GMP certified animal facility.

Cell Bank & Vaccine Characterisation

For all cell lines, the panel of tests must be carefully selected to control the pathogen safety risks, and the testing strategy is specific for each cell line/vaccine. To ensure that all potential risks are adequately addressed the testing services and experience available within VirusSure covers a wide range of tests including:

- Quantitative Real-Time PCR Assays
- Retrovirus Assays
- Cell Culture Based (*in vitro*) Assays
- *In vivo* Adventitious Agent Testing
- Immunological Assays
- Test System Development

Consultancy

We are experienced in the preparation of virus expert reports and are happy to assist you in developing your strategies for virus and prion safety testing.

To take advantage of our friendly and professional service, please contact us through our website at www.virusure.com, or via email to: Andy_Bailey@virusure.com or Ralf_Klein@virusure.com.



The founder and director of operations, Dr Andy Bailey, has been actively involved in the pathogen safety of biopharmaceuticals for over 15 years.

Originally a biochemist, Andy served for 9 years at the MRC Virology Unit in Glasgow, Scotland. In 1995, he moved as Director of Virus Validation services to Q-One Biotech Ltd, a leading company involved in the virus and prion bio-safety testing of biopharmaceuticals. Later he served at the Pathogen Safety group of Baxter Healthcare in Vienna, Austria.

Over the last 15 years, Andy has presented at numerous regulatory agencies either in support of products or as an invited speaker at expert workshops, including the UK MHRA, German PEI, French AFFSAPS, US FDA, EMEA and JMHLW (Japan).